RHOA and metabolic dysfunction-associated steatotic liver disease: Simvastatin, another mevalonate pathway suppressor, has been shown to prevent fibrosis and inflammation in NAFLD by suppressing RhoA- and Ras-mediated pathways without affecting steatosis [79].